Zimmer Biomet (NYSE:ZBH) Stock Gets Price Target Bump from Royal Bank Of Canada

Zimmer Biomet (NYSE:ZBH) had its target price increased by Royal Bank Of Canada from $110.00 to $125.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada‘s price objective would suggest a potential upside of 18.05% from the stock’s previous close.

Other research analysts have also issued reports about the company. Wells Fargo & Company upped their price target on Zimmer Biomet from $103.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Stifel Nicolaus set a $125.00 price objective on Zimmer Biomet in a report on Wednesday. BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Finally, Truist Financial lifted their target price on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $108.42.

Zimmer Biomet Stock Down 3.9%

NYSE ZBH traded down $4.26 on Thursday, hitting $105.89. 2,141,047 shares of the stock traded hands, compared to its average volume of 2,259,370. The company has a market capitalization of $20.20 billion, a P/E ratio of 25.76, a price-to-earnings-growth ratio of 2.33 and a beta of 0.50. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $112.54. The stock has a 50-day moving average of $94.90 and a 200 day moving average of $91.89. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The company had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.90 earnings per share. As a group, analysts expect that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In related news, insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds have recently modified their holdings of ZBH. Citizens National Bank Trust Department boosted its position in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 141 shares during the period. Valeo Financial Advisors LLC grew its position in Zimmer Biomet by 1.6% in the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after acquiring an additional 175 shares in the last quarter. Glenview Trust Co raised its holdings in shares of Zimmer Biomet by 3.7% during the 3rd quarter. Glenview Trust Co now owns 5,067 shares of the medical equipment provider’s stock valued at $450,000 after buying an additional 179 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Zimmer Biomet by 32.1% during the 1st quarter. Parallel Advisors LLC now owns 798 shares of the medical equipment provider’s stock valued at $72,000 after purchasing an additional 194 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Zimmer Biomet by 29.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 910 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 205 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, beating estimates, and adjusted EPS of $1.90 also topped consensus. The company raised its 2026 outlook, with strong hip and sports, extremities and trauma (S.E.T.) sales helping offset a difficult knee market. Zimmer Biomet Q3 results
• Positive Sentiment: Wells Fargo raised its price target to $113 from $103, while keeping an “equal weight” rating. Wells Fargo rating
• Neutral Sentiment: Sanford C. Bernstein lifted its target to $107 from $93 but maintained a “market perform” rating, signaling a more cautious view than a bullish upgrade. Bernstein rating
• Negative Sentiment: Knee sales were a drag, and reported diluted EPS fell 13.8% to $1.00; adjusted EPS was unchanged from a year earlier. These results point to continued product-mix and margin pressures despite the sales beat and improved outlook. Q3 profit and outlook report

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.